Can Vertex Keep Climbing?

Vertex Pharmaceuticals (VRTX) has had a great week. The drug maker released stellar late-stage clinical trial data late Tuesday for its new cystic fibrosis drug, and its share price has surged more than 20% in response. Is it too late to buy? Maxim Group analyst Jason McCarthy sees Vertex climbing another 34% in the next […]